GGHC
CCXI

Gilder Gagnon Howe & Co’s ChemoCentryx, Inc. CCXI Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-325,393
Closed -$1.81M – 268
2013
Q3 		$1.81M Sell
325,393
-878,703
-73% -$9.5M 0.03% 194
2013
Q2 		$17M Buy
+1,204,096
New +$15.6M 0.32% 76

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gilder Gagnon Howe & Co's CCXI Position: Q4 2013 in Review

Gilder Gagnon Howe & Co sold out of ChemoCentryx, Inc. (CCXI) in Q4 2013, closing a stake of 325,393 shares — an estimated $1.81M sold.

Gilder Gagnon Howe & Co first reported a position in CCXI in Q2 2013 and held it in 2 quarters. The position peaked at $17M in Q2 2013. 60 funds tracked by Wall St. Rank hold CCXI as of Q4 2013.

  • Gilder Gagnon Howe & Co reported no remaining ChemoCentryx, Inc. position as of Q4 2013 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 325,393 ChemoCentryx, Inc. shares in Q4 2013, an estimated $1.81M.
  • Gilder Gagnon Howe & Co first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's ChemoCentryx, Inc. position peaked at $17M in Q2 2013.
  • 60 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2013.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2013, filed 14 Feb 2014.